Is GERN or GMAB more undervalued in 2026?

CirclFi compares Geron Corporation (GERN) and Genmab A/S (GMAB) using 13 institutional-grade valuation models. GERN has a Quality of Company score of 4.6/10 while GMAB scores 6.7/10.

Which is a better buy — GERN or GMAB?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do GERN and GMAB valuations compare?

GERN at $1.25 and GMAB at $27.04 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

GERN vs GMAB Valuation Comparison 2026 — Intrinsic Value Analysis

GERN

Biotechnology

Geron Corporation

Quality

4.6

out of 10

Value Trap

LOW

Price

$1.25

Last close

Models

9/13

Active

GMAB

Biotechnology

Genmab A/S

Quality

6.7

out of 10

Value Trap

—

Price

$27.04

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	GERN Fair Value	GERN Upside	GMAB Fair Value	GMAB Upside
Bayesian DCF	Intrinsic	$0.32	-74.4%	$29.51	+9.1%
Earnings Power Value	Intrinsic	—	—	$22.31	-17.5%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.28	-78.2%	$59.18	+118.9%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for GERN vs GMAB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GERN vs GMAB — Which Stock Is More Undervalued?

GMAB scores higher with a 6.7/10 quality rating vs GERN's 4.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Geron Corporation (GERN) and Genmab A/S (GMAB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GERN currently trades at $1.25 with a QOC of 4.6/10, while GMAB trades at $27.04 with a QOC of 6.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).